Abstract
Primary Helicobacter pylori eradication rate using triple therapy (a proton pump inhibitor [PPI] + amoxicillin [AMPC] + clarithromycin [CAM], over 7 days) is showing a declining trend. In this study we report recent eradication rates and have evaluated the usefulness of a pack preparation of three drugs. H. pylori eradication rate was 85.1% (57/67) in 2004 but then fell to 75.2% (79/105) in 2005, 70.1% (68/97) in 2006 and 69.9% (58/83) in 2007. With the introduction of packs (lansoprazole [LPZ] 60 mg, AMPC 1500 mg, CAM 400 mg) the eradication rate recovered to 78.0% (110/141) in 2008. A comparative study in 2008 delineated that the eradication rate in the pack group (88.4%, 38/43) was significantly higher than that of the conventional group (73.5%, 72/98). These results suggest that packs of eradication medicine are useful in increasing eradication success.
Copyright 2010 Prous Science, S.A.U. or its licensors. All rights reserved.
MeSH terms
-
2-Pyridinylmethylsulfinylbenzimidazoles / administration & dosage
-
2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use*
-
Adult
-
Aged
-
Amoxicillin / administration & dosage
-
Amoxicillin / therapeutic use*
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / therapeutic use
-
Anti-Ulcer Agents / administration & dosage
-
Anti-Ulcer Agents / therapeutic use
-
Clarithromycin / administration & dosage
-
Clarithromycin / therapeutic use*
-
Drug Therapy, Combination
-
Female
-
Helicobacter Infections / drug therapy*
-
Helicobacter Infections / microbiology
-
Helicobacter pylori / drug effects
-
Helicobacter pylori / isolation & purification
-
Humans
-
Lansoprazole
-
Male
-
Middle Aged
-
Proton Pump Inhibitors / administration & dosage
-
Proton Pump Inhibitors / therapeutic use
-
Retrospective Studies
Substances
-
2-Pyridinylmethylsulfinylbenzimidazoles
-
Anti-Bacterial Agents
-
Anti-Ulcer Agents
-
Proton Pump Inhibitors
-
Lansoprazole
-
Amoxicillin
-
Clarithromycin